Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haploidentical stem cell transplantation for acute leukemia.

F Aversa1, A Terenzi, R Felicini

  • 1Department of Internal and Experimental Medicine, University of Perugia, Italy.

International Journal of Hematology
|November 15, 2002
PubMed
Summary

This study shows that a modified conditioning protocol for high-risk acute leukemia patients undergoing T-cell depleted hematopoietic stem cell transplant is effective. Selecting donors with NK cell alloreactivity improves outcomes, especially for acute myeloid leukemia (AML).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia.

Bone marrow transplantation·2023
Same author

Long-term assessment of clinical outcomes and disease progression in patients with corrected Tetralogy of Fallot.

European review for medical and pharmacological sciences·2021
Same author

The role of 3D imaging in the follow-up of patients with repaired tetralogy of Fallot.

European review for medical and pharmacological sciences·2019
Same author

Jon van Rood (1926-2017).

Bone marrow transplantation·2017
Same author

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Leukemia·2017
Same author

Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • High-risk acute leukemia presents significant treatment challenges.
  • Hematopoietic stem cell transplantation (HSCT) is a potential curative option.
  • T-cell depletion aims to reduce graft-versus-host disease (GvHD) and transplant toxicity.

Purpose of the Study:

  • To evaluate a modified TBI-Fludarabine conditioning protocol for T-cell depleted HSCT in high-risk acute leukemia.
  • To assess the impact of donor-recipient NK cell alloreactivity on outcomes.
  • To determine the safety and efficacy of this approach, particularly in older patients and those in relapse.

Main Methods:

  • Retrospective analysis of 53 high-risk acute leukemia patients (AML and ALL) undergoing HSCT.
  • Modified conditioning regimen: TBI, thiotepa, ATG, fludarabine, and T-cell depleted stem cells (CD34+ selected PBPCs).

Related Experiment Videos

  • Evaluation of engraftment, GvHD incidence, non-leukemic mortality, relapse rates, and event-free survival (EFS).

    • Main Results:

    • 98% engraftment rate observed.
    • The TBI-Fludarabine regimen was well-tolerated with low rates of severe mucositis and no veno-occlusive disease.
    • Acute GvHD (grade > or = II) occurred in only 4 patients, with one progressing to chronic GvHD.
    • Event-free survival was 60% for AML and 38% for ALL patients transplanted in CR.
    • AML patients with NK alloreactive donors showed significantly better EFS (70% vs 7%).

    Conclusions:

    • The modified TBI-Fludarabine conditioning protocol is safe and effective for high-risk acute leukemia patients.
    • Donor selection for NK cell alloreactivity is crucial for improving outcomes in AML patients.
    • Early stage disease and NK alloreactive donor selection are recommended for full haplotype mismatched transplantation.